Background:
This study was done to determine the representation of minorities, women, and the elderly in National Cancer Institute (NCI) clinical trials.
Methods:
This is an analysis in the NCI Clinical Data Update System. Patients were evaluated in breast, colorectal, lung, and prostate cancer trials from 2000 to 2019. Representation in a trial was determined by race/ethnicity, sex, and age. Secondarily, the change in trial participation by multivariable analysis by comparing years 2000 through 2004 to 2015 through 2019 was evaluated.
Results:
The cohort included 242,720 participants: 197,320 Non-Hispanic White (81.3%), 21,190 Black (8.7%), 11,587 Hispanic (4.8%), and 6880 Asian/Pacific Islander (2.8%). Black and Hispanic patients were underrepresented for colorectal (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.50-0.67; P < .001 and OR, 0.74; 95% CI, 0.64-0.87; P < .001, respectively), lung (OR, 0.83; 95% CI, 0.76-0.91; P < .001 and 0.66; 95% CI, 0.57-0.77; P < .001, respectively), and prostate cancer trials (OR, 0.85; 95% CI, 0.79-0.92; P < .001 and OR, 0.58; 95% CI, 0.51-0.66; P < .001) between 2015 and 2019. The odds of participation in 2015 to 2019 increased among Black patients in breast (OR, 2.19; 95% CI, 2.07-%2.32; P < .001), lung (OR, 1.54; 95% CI, 1.38-1.73; P < .001), and prostate cancer trials (OR, 1.14; 95% CI, 1.04-1.26; P < .001). The odds of participation in a trial among Hispanic patients increased for breast (OR, 3.32; 95% CI, 3.09-3.56; P < .001), colorectal (OR, 2.46; 95% CI, 2.04-2.96; P < .001), lung (OR, 3.88; 95% CI, 3.20-4.69; P < .001), and prostate cancer (OR, 1.70; 95% CI, 1.42-2.04; P = .005).
Conclusions:
This study identified that Black and Hispanic patients remain underrepresented in trials, but in recent years, participation has increased. These findings indicate that minority participation has increased over time, but further efforts are needed.
Citing Articles
The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.
Hanvey G, Johnson H, Cartagena G, Dede D, Krieger J, Ross K
J Clin Transl Sci. 2025; 9(1):e25.
PMID: 40052046
PMC: 11883616.
DOI: 10.1017/cts.2024.677.
Racial Disparities in Clinical Trial Enrollment Among Patients Diagnosed With Prostate Cancer: A Population-Based Cohort of Oncology Practices.
Wiesen B, Flaig T, Gershman B, Konety B, Warren A, Kuna E
Adv Urol. 2024; 2024:8871425.
PMID: 39735345
PMC: 11671626.
DOI: 10.1155/aiu/8871425.
Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.
Bain S, Belmar N, Hoff S, Husain M, Rasmussen S, Vilsboll T
Diabetes Ther. 2024; 16(1):15-28.
PMID: 39520501
PMC: 11759736.
DOI: 10.1007/s13300-024-01659-7.
Navigating the Path to Inclusion: Understanding Barriers and Facilitators to Clinical Trial Participation Among Chinese Older Adults in the United States with Multimorbidity.
Tarn D, Liu R, Pun T, Schwartz J
J Gen Intern Med. 2024; 40(2):393-401.
PMID: 39495453
PMC: 11802972.
DOI: 10.1007/s11606-024-09162-2.
Prevalence and proportion by age and sex of chronic health conditions in a large healthcare system.
Gronich N, Saliba W, Schwartz J
PLoS One. 2024; 19(9):e0308031.
PMID: 39325771
PMC: 11426542.
DOI: 10.1371/journal.pone.0308031.
Understanding and Addressing Prostate Cancer Disparities in Diagnosis, Treatment, and Outcomes Among Black Men.
Murphy A, Cottrell-Daniels C, Awasthi S, Katende E, Park J, Denis J
Cancer Control. 2024; 31:10732748241275389.
PMID: 39149902
PMC: 11329981.
DOI: 10.1177/10732748241275389.
Association Between State Medicaid Policies and Accrual of Black or Hispanic Patients to Cancer Clinical Trials.
Schpero W, Takvorian S, Blickstein D, Shafquat A, Liu J, Chatterjee A
J Clin Oncol. 2024; 42(27):3238-3246.
PMID: 39052944
PMC: 11408099.
DOI: 10.1200/JCO.23.01149.
Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics.
Altomare I, Wang X, Kaur M, Guadamuz J, Falk S, Xiao F
JNCI Cancer Spectr. 2024; 8(4).
PMID: 39041606
PMC: 11310105.
DOI: 10.1093/jncics/pkae060.
Women are Underrepresented in Non-small Cell Lung Cancer Clinical Trials: A Systematic Review.
Shah S, Krishnan V, Khan A, Fass L, Chaudhry T, Seder C
Ann Surg Oncol. 2024; 31(10):6673-6679.
PMID: 38987373
DOI: 10.1245/s10434-024-15720-z.
Social Determinants of Health and the Availability of Cancer Clinical Trials in the United States.
Sekar R, Herrel L, Stensland K
JAMA Netw Open. 2024; 7(5):e2410162.
PMID: 38713468
PMC: 11077395.
DOI: 10.1001/jamanetworkopen.2024.10162.
Variations in racial and ethnic groups' trust in researchers associated with willingness to participate in research.
Hu W, Bergren S, Dychtwald D, Ma Y, Dong X
Humanit Soc Sci Commun. 2024; 10.
PMID: 38650745
PMC: 11034911.
DOI: 10.1057/s41599-023-01960-z.
Impact of Clinical Trial Design on Recruitment of Racial and Ethnic Minorities.
Sheikh S, Bruno D, Sun Y, Deng V, McClelland 3rd S, Obi E
J Cancer Educ. 2024; 39(5):567-572.
PMID: 38637443
DOI: 10.1007/s13187-024-02440-x.
Reporting on invasive lobular breast cancer in clinical trials: a systematic review.
Van Baelen K, Van Cauwenberge J, Maetens M, Beck G, Camden A, Chase M
NPJ Breast Cancer. 2024; 10(1):23.
PMID: 38509112
PMC: 10954721.
DOI: 10.1038/s41523-024-00627-5.
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.
Hagege M, Bringuier M, Martinez-Tapia C, Chouaid C, Helissey C, Brain E
Age Ageing. 2024; 53(2).
PMID: 38346934
PMC: 10861365.
DOI: 10.1093/ageing/afae007.
Disparities in the Demographic Composition of The Cancer Imaging Archive.
Dulaney A, Virostko J
Radiol Imaging Cancer. 2024; 6(1):e230100.
PMID: 38240671
PMC: 10825717.
DOI: 10.1148/rycan.230100.
Describing Self-Advocacy in Underrepresented Women With Advanced Cancer.
Bell S, Bergeron R, Murray P, Gazaway S, Thomas T
Oncol Nurs Forum. 2023; 50(6):725-734.
PMID: 37874756
PMC: 11195808.
DOI: 10.1188/23.ONF.725-734.
MRI-Based Surrogate Imaging Markers of Aggressiveness in Prostate Cancer: Development of a Machine Learning Model Based on Radiomic Features.
Dominguez I, Rios-Ibacache O, Caprile P, Gonzalez J, San Francisco I, Besa C
Diagnostics (Basel). 2023; 13(17).
PMID: 37685317
PMC: 10486695.
DOI: 10.3390/diagnostics13172779.
Clinical atlas of rectal cancer highlights the barriers and insufficient interventions underlying the unfavorable outcomes in older patients.
Zhao Z, Lin J, Chen S, Wang X, Wang H, Xu G
Heliyon. 2023; 9(5):e15966.
PMID: 37215849
PMC: 10196521.
DOI: 10.1016/j.heliyon.2023.e15966.
Recruiting Indigenous Patients Into Clinical Trials: A Circle of Trust.
Mainous 3rd A, Kelliher A, Warne D
Ann Fam Med. 2023; 21(1):54-56.
PMID: 36690478
PMC: 9870649.
DOI: 10.1370/afm.2901.
Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019.
Lau S, Huang Y, Hsieh J, Wang S, Liu Q, Slattum P
JAMA Netw Open. 2022; 5(10):e2236149.
PMID: 36239939
PMC: 9568796.
DOI: 10.1001/jamanetworkopen.2022.36149.